Blog

Filippo Gallina: PD-L1 testing in the context of neoadjuvant chemo-immunotherapy

Photo from Filippo Gallina/X

Aug 3, 2024, 08:51

Filippo Gallina: PD-L1 testing in the context of neoadjuvant chemo-immunotherapy

Filippo Gallina, Research Fellow at McGill University Health, shared his recent article on X:

“Happy to share those considerations published on Lung Cancer Journal about PD-L1 testing in the context of neoadjuvant chemo-immunotherapy. Thanks to all the co-authors!”

Title: Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC

Authors: Filippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, Riccardo Tajè, Daniele Forcella, Enrico Melis, Fabiana Letizia Cecere, Francesca Fusco, Simonetta Buglioni, Paolo Visca, Paola Nisticò, Federico Cappuzzo, Jonathan Spicer

Source: Filippo Gallina/X

cancer chemo-immunotherapy Fabiana Cecere Federico Cappuzzo Filippo Tommaso Gallina Jonathan Spicer Lung Cancer Journal Nicla Porciello OncoDaily Oncology PD-L1 testing Vittoria Balzano

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity